Vistin Pharma (VISTN.OL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

VISTN.OL · Stock Price

NOK 22.40-2.10 (-8.57%)

Market Cap: $107.5M

Historical price data

Market Cap: $107.5MFounded: 2015HQ: Oslo, Norway

Sector Ranking#175 in Small Molecule Drugs

Overview

Vistin Pharma's mission is to be a leading global supplier of high-quality Metformin API, balancing growth with sustainable and responsible manufacturing. The company has achieved a defensible market position as Europe's dedicated producer, supplying ~10% of global demand to a diverse client base of international pharmaceutical companies. Its core strategy is focused on operational excellence and cost leadership in a single API, currently executing a capacity expansion to >7,000 MT/year to capture a larger share of the growing diabetes market. Financial performance is characterized by sustained revenue growth, underpinned by its specialized manufacturing platform.

Metabolic DiseaseType 2 Diabetes

Technology Platform

Specialized, dedicated manufacturing platform for the high-volume synthesis and processing of Metformin Hydrochloride API, emphasizing high purity (nitrosamine-free), process optimization, and scalable, cGMP-compliant production.

Funding History

1

IPOUndisclosedUndisclosedJun 5, 2015

Opportunities

The primary opportunity lies in capturing a larger share of the growing global metformin market through its capacity expansion, targeting ~15% share.

Additionally, pharmaceutical industry trends towards supply chain diversification and stringent quality control directly benefit Vistin's European, high-quality manufacturing base.

Risk Factors

Key risks include extreme product concentration on a single API (metformin), exposure to generic drug pricing pressure, regulatory compliance risks for its manufacturing facility, and execution risks associated with its major capacity expansion project.

Competitive Landscape

Vistin competes against large-scale, low-cost API manufacturers in India and China. Its competitive advantage is not on price but on quality (nitrosamine-free), supply chain security as a European producer, strong regulatory standing, and a clear sustainability profile, carving out a defensible niche.